Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 56Breast Neoplasms 7Bulbo-Spinal Atrophy, X-Linked 4Neoplasms 3Neoplasm Metastasis 3Triple Negative Breast Neoplasms 2Salivary Gland Neoplasms 2Stage I Prostate Adenocarcinoma 1Recurrence 1Paget Disease, Extramammary 1PSA Level Greater Than Two 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Lower Urinary Tract Symptoms 1Gynecomastia 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Carcinoma, Transitional Cell 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms, Male 1Adenocarcinoma 1

Interventions

Tadalafil 2udenafil 1mirabegron 1bicalutamide 1alpha-Tocopherol 1Vitamin E 1Tamoxifen 1Sildenafil Citrate 1Pentoxifylline 1Long-Term Synaptic Depression 1GPI 1485 1Erythropoietin 1Dutasteride 1Atorvastatin 1Arginine 1ArginMax 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Erectile Dysfunction × bicalutamide × Clear all
NCT00866554 2023-06-02

Efficacy and Toxicity of Bicalutamide and Dutasteride vs. Standard Care for Prostate Cytoreduction for Brachytherapy

CHU de Quebec-Universite Laval

Phase 2 Completed
60 enrolled
Genitourinary

Erectile Dysfunction, Prostatic Neoplasms, Lower Urinary Tract Symptoms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡